Dipharma S.A. is a Swiss specialty pharmaceutical company, developing high quality, improved, medicines for rare diseases. Dipharma S.A. is part of a third-generation group of family-owned companies that have grown to a global presence.
With a portfolio of generic orphan products for the treatment of Phenylketonuria, Gaucher Disease, Hereditary Tyrosinemia Type 1, Urea Cycle Disorders and others, Dipharma S.A. provides improved solutions for patients affected by inborn metabolic diseases at an affordable cost and with a global reach.
Piazza Col. C. Bernasconi 5
|T.: +41 91 60 11 700|
|Contact name: Marc-Olivier Geinoz|
Main activities Licensing-In ● Licensing-Out ● Co-development ○ Trading ●
Drug stages Registration ● Market ● Generic Plus (505B2) ○ Generic ● Life cycle management ●
Therapeutic areas Metabolism ●
Markets CH ○ EU Top 5 ● Rest of Europe ○ USA and Canada ● LATAM ○ MENA ○ BRICS ○ ASEAN ○ Africa ○ Australia ○ Brazil ○ China ○ Japan ○ Korea ○